Home・Aktien・Vericel Corp

Vericel Corp

Geschlossen

BrancheGesundheitswesen

43.17 2.57

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

42.09

Max

43.2

Schlüsselkennzahlen
By Trading Economics
Einkommen	13M 6.3M
Verkäufe	9M 77M
KGV Branchendurchschnitt	88.125 57.366
EPS	0.04
Gewinnspanne	8.136
Angestellte	398
EBITDA	8.5M 5.6M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+48.16% upside

Dividenden
By Acuity
Nächstes Ergebnis	5. Nov. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-148M 2.2B
Vorheriger Eröffnungskurs	40.6
Vorheriger Schlusskurs	43.17

Nachrichtenstimmung

By Acuity

100%

329 / 340 Ranking in Healthcare

Vericel Corp Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

20. Aug. 2026, 20:02 UTC

Correlated Moves

Vericel Corp shares are declining amid broader market pressures, reflecting negative sentiment from disappointing sales growth and guidance from Walmart Inc.

19. Aug. 2026, 23:26 UTC

Vericel Corp shares are lower in after-market trading, reflecting ongoing weakness. The stock remains near the lower end of its one-month range.

18. Aug. 2026, 19:26 UTC

Vericel Corp shares are higher today, reflecting positive market sentiment despite no specific news. The stock remains up since Monday's close.

13. Aug. 2026, 19:43 UTC

Vericel Corp shares are lower today, reflecting ongoing weakness below the 20-day moving average and near the lower end of their one-month range.

11. Aug. 2026, 19:46 UTC

News

Vericel Corp shares are higher as analysts maintain a "Moderate Buy" consensus, with HC Wainwright's target at $70 and Truist raising its target to $58.

10. Aug. 2026, 19:46 UTC

Correlated Moves

Vericel Corp shares are lower today, reflecting a broader market decline and volatility amid uncertainty over the Federal Reserve's interest rate policy.

7. Aug. 2026, 19:16 UTC

Correlated Moves

Vericel Corp's shares rise, supported by gains in the ARK Genomic Revolution ETF and Russell 2000 Index, despite earlier fluctuations in trading.

6. Aug. 2026, 19:26 UTC

Correlated Moves

Vericel Corp shares declined during Thursday's session, tracking broader market trends. The stock remains near the lower end of its one-month trading range.

5. Aug. 2026, 19:26 UTC

Correlated Moves

Vericel Corp shares are lower today, reflecting broader market trends as the Russell 2000 Index declines. The stock remains below its 20-day moving average.

3. Aug. 2026, 20:03 UTC

Correlated Moves

Vericel Corp shares are advancing, supported by significant gains in the broader market and major tech stocks, contributing to positive investor sentiment.

31. Juli 2026, 20:02 UTC

Correlated Moves

Vericel Corp's price is lower today, influenced by declines in the Biotechnology sub-sector and a falling Russell 2000 Index.

30. Juli 2026, 20:36 UTC

Correlated Moves

Vericel Corp shares gained in after-market trading, aligning with a rising Russell 2000 Index. The stock remains above its 20-day moving average.

29. Juli 2026, 19:27 UTC

Correlated Moves

Vericel Corp shares declined during Wednesday's session, continuing a downward trend since Tuesday's close, amid broader market weakness reflected in the Russell 2000 Index.

28. Juli 2026, 21:02 UTC

Vericel Corp shares are lower in after-market trading, reflecting broader market caution amid declines in the Nikkei 225 Index and technology sector concerns.

27. Juli 2026, 20:31 UTC

Vericel Corp shares declined during after-market hours amid unusual selling pressure. The stock remains below its 20-day moving average with no specific news identified.

24. Juli 2026, 19:46 UTC

Correlated Moves

Vericel Corp reported first-quarter revenue of $39.2 million, missing estimates. Shares are lower amid broader market declines affecting small-cap biotechnology stocks.

22. Juli 2026, 20:13 UTC

Vericel Corp shares are trading higher in after-market hours, influenced by broader market volatility amid rising crude oil prices and geopolitical tensions.

21. Juli 2026, 14:31 UTC

Vericel Corp shares are higher, supported by overall market momentum and a recovery in Asian markets, particularly the Nikkei 225 Index.

20. Juli 2026, 17:46 UTC

Correlated Moves

Vericel Corp shares are lower today, aligning with a decline in the ARK Genomic Revolution ETF and the Russell 2000 Index.

Peer-Vergleich

Kursveränderung

Vericel Corp Prognose

Kursziel

By TipRanks

48.16% Vorteil

12-Monats-Prognose

Durchschnitt 62.67 USD 48.16%

Hoch 72 USD

Tief 58 USD

Basierend auf 4 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Vericel Corp – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

4 ratings

Buy

Halten

Sell

Basierend auf 4 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Vericel Corp – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Vericel Corp

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.